Artemisinin	O
inhibits	O
tumor	B-Cancer
lymphangiogenesis	O
by	O
suppression	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
C	O
.	O

We	O
have	O
previously	O
reported	O
that	O
dihydroartemisinin	O
is	O
found	O
to	O
have	O
a	O
potent	O
ability	O
in	O
influencing	O
lymphatic	B-Cell
endothelial	I-Cell
cell	I-Cell
migration	O
and	O
tube	B-Tissue
formation	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
artemisinin	O
on	O
tumor	B-Cancer
growth	O
,	O
lymphangiogenesis	O
,	O
metastasis	O
and	O
survival	O
in	O
mouse	O
Lewis	B-Cancer
lung	I-Cancer
carcinoma	I-Cancer
(	O
LLC	B-Cancer
)	O
models	O
.	O

We	O
found	O
that	O
orally	B-Organism_subdivision
administered	O
artemisinin	O
inhibited	O
lymph	B-Multi-tissue_structure
node	I-Multi-tissue_structure
and	O
lung	B-Organ
metastasis	O
and	O
prolonged	O
survival	O
without	O
retarding	O
tumor	B-Cancer
growth	O
.	O

Consistent	O
with	O
the	O
decrease	O
in	O
lymph	B-Multi-tissue_structure
node	I-Multi-tissue_structure
metastasis	O
,	O
tumor	B-Cancer
lymphangiogenesis	O
and	O
expression	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
C	O
(	O
VEGF	O
-	O
C	O
)	O
was	O
significantly	O
decreased	O
in	O
artemisinin	O
-	O
treated	O
mice	O
,	O
as	O
compared	O
to	O
control	O
mice	O
.	O

Furthermore	O
,	O
IL	O
-	O
1beta	O
-	O
induced	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
activation	O
and	O
upregulation	O
of	O
VEGF	O
-	O
C	O
mRNA	O
and	O
protein	O
in	O
LLC	B-Cell
cells	I-Cell
was	O
also	O
suppressed	O
by	O
artemisinin	O
or	O
by	O
the	O
p38	O
MAPK	O
inhibitor	O
SB	O
-	O
203580	O
,	O
suggesting	O
that	O
p38	O
MAPK	O
could	O
serve	O
as	O
a	O
mediator	O
of	O
proinflammatory	O
cytokine	O
-	O
induced	O
VEGF	O
-	O
C	O
expression	O
.	O

These	O
data	O
indicate	O
that	O
artemisinin	O
may	O
be	O
useful	O
for	O
the	O
prevention	O
of	O
lymph	B-Multi-tissue_structure
node	I-Multi-tissue_structure
metastasis	O
by	O
downregulating	O
VEGF	O
-	O
C	O
and	O
reducing	O
tumor	B-Cancer
lymphangiogenesis	O
.	O

